|
Main
|
|
Note: This record shows only the 20 elements of the WHO Trial Registration Data Set. To view changes that have been made to the source record, or for additional information about this trial, click on the URL below to go to the source record in the primary register. |
|
Register:
|
ClinicalTrials.gov |
|
Last refreshed on:
|
17 October 2012 |
|
Main ID: |
NCT00134381 |
|
Date of registration:
|
22/08/2005 |
|
Primary sponsor: |
|
|
Public title:
|
Green Tea and Ultraviolet Light-induced Skin Damage
|
|
Scientific title:
|
The Effects of Topically Applied Constituents of Green Tea on UV Induced Increase in p53 and Apoptotic Markers in the Skin of Human Volunteers |
|
Date of first enrolment:
|
May 2003 |
|
Target sample size:
|
168 |
|
Recruitment status: |
Active, not recruiting |
|
URL:
|
http://clinicaltrials.gov/show/NCT00134381 |
|
Study type:
|
Interventional |
|
Study design:
|
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment
|
|
|
Countries of recruitment
|
|
United States
| | | | | | | |
|
Contacts
|
|
Name:
|
Melissa Magliocco, MD |
|
Address:
|
|
|
Telephone:
|
|
|
Email:
|
|
|
Affiliation:
|
University of Medicine and Dentistry New Jersey |
| | |
|
Key inclusion & exclusion criteria
|
Inclusion Criteria:
- The subjects will be normal adult volunteers who are 18 to 65 years of age.
Exclusion Criteria:
- Subjects who drink more than two cups of coffee, tea, or caffeinated soda/beverages per day.
- Subjects who are unable to get an erythemic response (i.e., a sunburn).
Age minimum:
18 Years
Age maximum:
65 Years
Gender:
Both
|
|
Health Condition(s) or Problem(s) studied
|
|
Healthy
|
|
Intervention(s)
|
|
Drug: Green Tea
|
|
Primary Outcome(s)
|
|
Enhancement of UV-induced p53 and markers of apoptosis by green tea compounds
[Time Frame: 48 hrs]
|
|
Secondary Outcome(s)
|
|
Reduction of UV-induced erythema by green tea compounds
[Time Frame: 48 hrs]
|
|
Source(s) of Monetary Support
|
|
Please refer to primary and secondary sponsors
|
|